

Innovhem to present New data on single-cell quantification of HbF at the 2024 American Society of Hematology (ASH) Annual Meeting

- **One poster presentation to feature new data from FCDREP studies, highlighting HbF and HbS expression at the single-cell level on patients treated with hydroxyurea.**

Paris, France – November 15th, 2024

Innovhem, a French company developing first-in-class medical devices to improve the clinical management of patients with Sickle Cell Disease, today announced that data from our FCDREP studies on single-cell quantification of HbF and HbS will be presented at the 66th Annual Meeting of the American Society of Hematology (ASH), to be held December 7-10, 2024 in San Diego, California, as well as online. This presentation will highlight the value of using single-cell Hb quantification to better understand the mechanisms of treatments aimed at increasing HbF expression, as well as their evaluation and patient follow-up.

Details of the poster presentations:

Abstract #1105

- **Title:** Single Cell Hemoglobin Quantification Reveals HbF and HbS Increases in Sickle Erythrocytes from Patients Treated with Hydroxyurea
- **Presenting Author:** Pablo Bartolucci, MD,PhD, University Paris-Est-Creteil, IMRB, Inserm U955,, Henri Mondor University Hospitals, APHP, Sickle Cell ReferralCenter-UMGGR, Creteil, France
- **Program:** Oral and Poster Abstracts
Session: 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster I
Hematology Disease Topics & Pathways: Research, Sickle Cell Disease, Translational Research, Hemoglobinopathies, Diseases
- **Presentation date and time:** Saturday, December 7, 2024, 5:30 PM-7:30 PM